CAR-T therapy for multiple myeloma or plasmacytoma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells given as part of an early treatment plan for multiple myeloma or plasmacytoma. The goal is to see if this approach can help achieve a deep remission, especially after a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma or a plasmacytoma (a type of blood cancer).
- The goal of treatment is to achieve a complete remission (no signs of cancer).
- Your doctor expects you to live at least 12 weeks.
- You have had an autologous stem cell transplant (using your own stem cells) before, or are willing to have one.
- You have good veins for a procedure called apheresis (removing blood cells).
- You are not pregnant or breastfeeding and do not have an active infection like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
This trial tests combining CAR-T cell therapy with a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to see if this approach can help when other treatments have failed.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.